CA2722996A1 - Analogues peptidiques du gluten non inflammatoires utilises comme biomarqueurs de la maladie coeliaque - Google Patents

Analogues peptidiques du gluten non inflammatoires utilises comme biomarqueurs de la maladie coeliaque Download PDF

Info

Publication number
CA2722996A1
CA2722996A1 CA2722996A CA2722996A CA2722996A1 CA 2722996 A1 CA2722996 A1 CA 2722996A1 CA 2722996 A CA2722996 A CA 2722996A CA 2722996 A CA2722996 A CA 2722996A CA 2722996 A1 CA2722996 A1 CA 2722996A1
Authority
CA
Canada
Prior art keywords
peptide
gluten
mer
seq
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2722996A
Other languages
English (en)
Inventor
Michael Thomas Bethune
Chaitan Khosla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2722996A1 publication Critical patent/CA2722996A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2722996A 2008-05-16 2009-05-13 Analogues peptidiques du gluten non inflammatoires utilises comme biomarqueurs de la maladie coeliaque Abandoned CA2722996A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5394908P 2008-05-16 2008-05-16
US61/053,949 2008-05-16
PCT/US2009/002997 WO2009139887A2 (fr) 2008-05-16 2009-05-13 Analogues peptidiques du gluten non inflammatoires utilisés comme biomarqueurs de la maladie coeliaque

Publications (1)

Publication Number Publication Date
CA2722996A1 true CA2722996A1 (fr) 2009-11-19

Family

ID=41319214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2722996A Abandoned CA2722996A1 (fr) 2008-05-16 2009-05-13 Analogues peptidiques du gluten non inflammatoires utilises comme biomarqueurs de la maladie coeliaque

Country Status (4)

Country Link
EP (1) EP2277046A2 (fr)
AU (1) AU2009246925A1 (fr)
CA (1) CA2722996A1 (fr)
WO (1) WO2009139887A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367561B1 (fr) 2008-11-30 2015-05-20 Immusant, Inc. Compositions et procédés pour le traitement d'une maladie coeliaque
EP2673292A4 (fr) * 2011-02-08 2014-05-21 Phadia Ab Antigènes de blé et peptides pour le diagnostic de l'hypersensibilité induite par le blé
US20160041148A1 (en) * 2013-03-14 2016-02-11 Immusant,Inc. Placebo-controlled gluten challenge method
CA2923822A1 (fr) 2013-09-10 2015-03-19 Immusant, Inc. Dosage d'une composition peptidique de gluten
ES2556177B1 (es) * 2014-07-09 2016-10-20 Universidad De Sevilla Detección de péptidos del gluten en fluidos humanos
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
JP6738888B2 (ja) * 2016-02-23 2020-08-12 田中貴金属工業株式会社 グリアジン検出用免疫クロマト分析装置、免疫クロマト分析キットおよび免疫クロマト分析方法
WO2018005688A1 (fr) * 2016-06-28 2018-01-04 Immusant, Inc. Compositions et procédés de diagnostic de la maladie coeliaque à l'aide de cytokines/chimiokines circulantes
WO2019147990A1 (fr) * 2018-01-26 2019-08-01 The Regents Of The University Of California Méthodes et compositions concernant la perméabilité intestinale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
WO2008052185A2 (fr) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Matériaux et procédés pour le traitement de la maladie cœliaque

Also Published As

Publication number Publication date
EP2277046A2 (fr) 2011-01-26
AU2009246925A1 (en) 2009-11-19
WO2009139887A3 (fr) 2010-02-04
WO2009139887A2 (fr) 2009-11-19

Similar Documents

Publication Publication Date Title
CA2722996A1 (fr) Analogues peptidiques du gluten non inflammatoires utilises comme biomarqueurs de la maladie coeliaque
Pulido et al. Introduction of oats in the diet of individuals with celiac disease: a systematic review
Busby et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation
US7462688B2 (en) Peptides for diagnostic and therapeutic methods for celiac sprue
Liddle et al. Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol
Pruimboom et al. The opioid effects of gluten exorphins: asymptomatic celiac disease
Gass et al. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat
Hill et al. Anti-tissue transglutaminase antibodies and their role in the investigation of coeliac disease
JP2013129672A (ja) 代謝障害の診断及び治療方法
EA037603B1 (ru) Композиции и способы для лечения целиакии спру
AU2015249383A1 (en) Compositions comprising gluten peptides and uses thereof
Di Stasio et al. Comparative analysis of in vitro digestibility and immunogenicity of gliadin proteins from durum and einkorn wheat
US20160041148A1 (en) Placebo-controlled gluten challenge method
Tye-Din et al. Immunopathogenesis of celiac disease
Zhu et al. How does a celiac iceberg really float? The relationship between celiac disease and gluten
WO1980001415A1 (fr) Essai de la fonction exocrine du pancreas
US20110065758A1 (en) Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions
DK2203188T3 (en) Biomarker for measuring the efficacy of drugs in enteropathic disease
WO2011000773A1 (fr) Test d'efficacité dans le traitement de la maladie cœliaque
JP2008533013A (ja) 空腹時の血漿コレシストキニン濃度を高めるのに活性を示すポテトプロテナーゼ阻害剤ｉｉ
D'Alessio et al. Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men
Baldassarre et al. Celiac disease: pathogenesis and novel therapeutic strategies
US8569448B2 (en) NMDAR biomarkers for diagnosis and treatment of traumatic brain injury and other disorders
RU2690665C2 (ru) Обнаружение глютеновых пептидов в жидкостях организма человека
US20130065255A1 (en) Biomarker to Measure Drug Efficacy in Enteropathic Disease

Legal Events

Date Code Title Description
FZDE Discontinued